Innoviva, Inc. (INVA) - Due Diligence

hourglass

Loading…

Preparing the latest DD data, styles and content.

74OpportunityDD: Aug 02, 2026Analyst: 77

paidPrice at analysis date

USD 21.0 (02/08/2026)

domainMkt cap

$1.55B

pie_chartShares

73.81M

candlestick_chart52W

$16.52-25.15

trending_downShort interest

9.0%

INFONASDAQHealth Care159 employeesFounded 1996

Verdict: Favorable Risk/Reward — Diversified royalty-plus-commercial platform trading at ~10x fwd EPS

Cash-generative GSK royalty (BREO/ANORO) funds a scaling critical-care/anti-infective commercial arm (IST) and a $773M strategic investment book anchored by Armata. Balance sheet is net-cash ex-convertibles; forward P/E ~10x vs pharma sector ~19x. Main overhangs: royalty attrition (-4% Q1 YoY), governance concentration around Sarissa/Denner, and market discount on the mark-to-market Armata position.

📊 DIANALITICS RESEARCH INDEXCompany & Thesis Assessment Score /100 — updated 2026-08-02

Innoviva, Inc. (INVA)

Biotechnology · NASDAQ · Burlingame, CA

"Cheap on forward earnings, funded by a real royalty stream, discounted on optics."

Net cash ex-notes $125M buyback active Fwd P/E 10.5x Royalty attrition Sarissa governance

Fin. strength

/20 pts

EBITDA/FCF

/15 pts

Debt/leverage

/15 pts

Stage/business

/15 pts

Catalysts

/10 pts

Reg. risk

/8 pts

Risk/reward

/7 pts

Management

/5 pts

Sector/macro

/3 pts

Compliance

/2 pts

Fair Value Estimate — Sum-of-the-Parts (Royalty NPV + IST EV/Rev + Investments NAV)

Fair value base case

USD 32.5

Range: USD 22.0-USD 45.0

Price at analysis date: USD 21.0 (02/08/2026)

Base upside/downside: +55%

SotP with three main pools + capital structure adjustments. Implied blended EV/EBITDA at FV = 8.7x, within peer range 11-23x. Cross-check with forward P/E: $32.50/$2.20 = 14.8x, coherent with pharma sector median 19x minus liquidity discount. Sensitivity: royalty multiple is largest lever (±$3.2/sh per 1x); Armata NAV second largest (±$5/sh per 30% price move). FV vs consensus $35.50 = -9% (within ±25% acceptable band). ⚠️ Not investment advice.

Component	Assumption	USD/share
GSK royalty stream (BREO/ANORO)	~$235M FY26E royalty (Q1 annualized -4% YoY trajectory) × 5.0x FCF multiple (declining perpetuity, 90-95% cash conversion) = $1,175M / 73.81M sh	+15.9
IST commercial (GIAPREZA, XACDURO, XERAVA, ZEVTERA)	~$195M FY26E revenue (+37% Q1 YoY, guided decel) × 3.0x fwd EV/Rev (below HALO 6x, LGND 8x — reflects earlier commercial stage) = $585M / 73.81M sh	+7.9
Strategic investments (Armata, ISP Fund, other)	$773M mark-to-market Q1 2026 × 0.70 illiquidity/concentration haircut (Armata is $603M of the $773M, controlling stake) = $541M / 73.81M sh	+7.3
Net cash (cash - convertibles)	$603M cash - $412M non-current liabilities (mostly $261M 2028 conv notes + deferred tax) = $191M / 73.81M sh	+2.6
Buyback accretion (12-mo)	$125M authorization × 40% likely execution rate at ~$21 avg = ~2.4M shares retired = ~3.2% share count reduction, applied to per-share FV base	+0.8
Convertible dilution (2028 notes)	$261M @ 2.125% conv price ~$25 = ~10.4M dilutive shares if in-the-money; base case out-of-money at $21, but haircut for optionality	-2.0
FV base case	Sum: 15.9 + 7.9 + 7.3 + 2.6 + 0.8 - 2.0 = 32.5	$32.50

Bull

$42–$50

Probability: 20%

GSK royalty stabilizes (Advair generic pressure reversed), IST scales to $250M+ FY27, Armata reaches a phage therapy milestone (Phase 3 readout / partnership), $125M buyback fully executed. Multiple re-rates to 14-16x fwd P/E in line with peer median.

Base

$28–$36

Probability: 55%

Royalty declines 4-6%/yr as modeled, IST grows +25% to ~$200M FY26E, Armata holds MTM value, $50M buyback executed. Multiple stays at 12-14x fwd P/E. Aligned with analyst consensus $35.50.

Bear

$14–$20

Probability: 25%

GSK royalty accelerates decline (-10%+/yr from patent cliff), Armata suffers Phase 3 setback triggering $200-300M markdown, IST growth stalls at $150M. Multiple compresses to 7-8x fwd P/E on quality concerns.

Methodology: SotP with three main pools + capital structure adjustments. Implied blended EV/EBITDA at FV = 8.7x, within peer range 11-23x. Cross-check with forward P/E: $32.50/$2.20 = 14.8x, coherent with pharma sector median 19x minus liquidity discount. Sensitivity: royalty multiple is largest lever (±$3.2/sh per 1x); Armata NAV second largest (±$5/sh per 30% price move). FV vs consensus $35.50 = -9% (within ±25% acceptable band). ⚠️ Not investment advice. Not investment advice.

check_circle

Q2 2026 earnings on 2026-08-10 — near-term binary catalyst

Next earnings release scheduled 2026-08-10 (T+8 days from report). Consensus centered on continued IST growth (+30% YoY trajectory) and stable GSK royalty run-rate. Beat could re-price the 10x fwd P/E discount; miss re-focuses attention on royalty decline curve.

Note: Methodology note: INVA is a hybrid royalties + specialty commercial + strategic investments platform. SotP is the natural framework (royalty stream valued as declining perpetuity, IST as forward-EV/Revenue, strategic book at NAV with illiquidity discount). Trailing P/E (3.68x) is optically compressed by ~$500M FY25 mark-to-market gains on Armata — ignore it as a signal; use forward EPS and SotP.

📊 Capital Structure · Short Interest · Buyback & Dilution

🟡 Short Interest

9.0%

6.6M shares shorted of 73.81M outstanding (float basis). Up 12.6% from prior period but down 33.6% YoY. Interpretation: moderate short positioning, no squeeze thesis; some concern on royalty decline.

🟢 Share dilution (1Y)

-2.1%

From ~75.4M to 73.81M shares. Reduction driven by 2025 buyback executions net of employee equity vesting. No open-market equity raises; $261M 2028 convertibles are the only dilution overhang (conv price ~$25).

🟢 Buyback

$125M

New authorization announced Nov 2025 (no expiry). Signals management sees stock as undervalued at current levels. Capital priority ranked below strategic investments (Armata support) but ahead of dividends.

Short Interest — context

INVA — 9.0%

9.0%

Insider activity: March 2025 — Alexander Denner (Sarissa Capital, chairman) sold ~1.63M shares for ~$28.4M at $17.50-17.63/sh. This is >12 months old so falls outside the 12-mo mandatory-disclosure window, but relevant for governance context (Sarissa remains largest shareholder). Recent 2026 insider activity limited to CAO tax-withholding on RSU vesting (immaterial). No SEC investigation, no class action filed, no short-seller report identified as of Aug 2026.

$Financial analysis — FY 2025 & H1 2026 trajectory

Revenue TTM

$420.7M

+13.7% YoY — IST +37% offsetting royalty -4%

Cash & equivalents

$603.1M

39% of market cap — ample runway

Fwd P/E (FY26E)

10.5x

vs sector 19x = -45% discount

Strategic investments

$773M

Armata concentration 78%

Item	FY2023	FY2024	FY2025	Q1 2026	Guidance FY2026E
Total revenue ($M)	384.2	358.7	411.3	98.0	~430-450
Royalty revenue ($M)	253.1	245.4	250.5	58.6	~230-240 (declining)
Product sales / IST ($M)	131.1	113.3	160.8	41.4	~195-210
Net income ($M)	66.7	23.4	271.2	187.0	~180-220 (ex-MTM)
EPS (basic $)	0.89	0.32	4.02	2.22	~2.20-2.80
Cash ($M)	367.4	396.2	544.8	603.1	~620-680

Note: FY25 net income and Q1'26 heavily inflated by $500M+ combined mark-to-market gains on Armata equity position. Operating earnings run-rate is ~$100-130M/yr; forward EPS guidance normalized excludes MTM swings.

Quarterly dynamics — last 5 quarters
Metric	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue ($M)	88.6	100.3	107.8	114.6	98.0
Royalty ($M)	61.3	67.3	65.5	62.9	58.6
Product sales ($M)	30.3	35.5	42.3	51.7	41.4
Net income ($M)	-46.6	63.7	89.9	164.2	187.0
EPS diluted ($)	-0.63	1.01	1.22	2.19	2.22
End-of-period cash ($M)	438	478	525	545	603

Financial position and sustainability

Cash / market cap

39%

IST growth YoY (Q1'26)

+37%

Royalty decay YoY (Q1'26)

-4.4%

Debt/EBITDA (fwd)

~1.5x

Analyst upside to consensus

+69%

account_tree

Business model — Hybrid royalty + specialty commercial + healthcare-asset holdco

A three-legged stool: royalty cash flow funds commercial scaling and strategic bets

Innoviva operates as a diversified biopharma holdco with three distinct value pools. The GSK royalty portfolio (BREO/ANORO ELLIPTA respiratory franchise) delivers ~$240M/yr of near-pure-margin cash flow that requires no operating investment. This funds Innoviva Specialty Therapeutics (IST), a critical-care and anti-infective commercial business built via M&A (Entasis, La Jolla) with four launched products: GIAPREZA (septic shock vasopressor), XACDURO (Acinetobacter infections), XERAVA (complicated intra-abdominal infections), ZEVTERA (bacteremia). Third leg is a $773M strategic investments book led by a controlling stake in Armata Pharmaceuticals (phage therapy platform) plus ISP Fund and other convertible positions. Nortiva Bio spun out in June 2026 as a separate clinical-stage entity for long-acting oral medicines (LYNX platform).

GSK Royalty (BREO/ANORO) ~$230-240M FY26E (~55% rev) 🔴 declining Royalty on respiratory franchise (COPD/asthma). ~95% cash margin, zero opex. Slowly declining -4-6%/yr as generic pressure builds on Advair and adjacent products. Long-tail value even at attrition rates. IST — Specialty Commercial ~$195-210M FY26E (~45% rev) 🟢 ramping +37% GIAPREZA + XACDURO drive US growth; XERAVA/ZEVTERA add optionality. New Dr. Reddy's ex-US distribution deal for XACDURO (Jun 2026) opens international footprint. GM target 65-70%; commercial infrastructure now scaled. Strategic Investments (Armata + others) $773M NAV (Q1'26 MTM) 🟡 binary Controlling stake in Armata (phage therapy, FDA Fast Track), $138M other convertibles/equity, $32M ISP Fund. Illiquid, MTM-volatile. Extended $25M credit line to Armata (Jan 2029 maturity). Nortiva Bio spinout June 2026.

gavel

Legal, regulatory and risk analysis

GSK royalty attrition

Moderate

BREO/ANORO royalty -4% Q1'26 YoY. Generic pressure on Advair and adjacent inhaled respiratory products accelerates over 3-5 years. Represents 55%+ of current revenue and dominant share of cash-flow contribution — largest single-value driver.

Armata concentration & liquidity

High

$603M of $773M strategic book is Armata equity. Illiquid controlling stake — cannot exit quickly. Phage therapy is early clinical (Phase 3), regulatory path uncertain. Single Phase 3 setback would trigger $200-300M markdown.

Sarissa/Denner governance

Moderate

Sarissa Capital (Alexander Denner) is largest shareholder and effectively controls strategic direction. March 2025 $28M insider sale creates alignment concerns. Track record on Armata investment is questioned by some analysts. Concentration limits governance checks.

Convertible refinancing 2028

Moderate

$261M 2028 convertible notes (2.125% coupon, conv price ~$25) mature March 2028. If stock stays below $25, notes must be refinanced or repaid in cash. Cash balance covers it 2.3x but reduces flexibility for buyback / M&A / IST scaling.

Balance sheet strength

Positive

$603M cash covers all $412M debt/deferred tax with $190M net cash surplus. Zero refinancing risk pre-2028. Royalty cash flow adds $20-25M/qtr operational cushion. No going-concern flags.

Buyback commitment

Positive

$125M authorization (Nov 2025, no expiry) is credible capital return signal. Represents ~8% of market cap. Board using cash discipline to backstop valuation while awaiting IST scale-up and Armata catalysts.

Anti-infective reimbursement

Moderate

XACDURO/ZEVTERA face DRG-bundled hospital reimbursement pressure. Anti-infective category historically difficult commercially (see Achaogen, Melinta bankruptcies). IST is executing better than sector average but category headwind is structural.

Clean legal profile

Positive

No pending securities class actions, no SEC investigations, no short-seller reports identified as of Aug 2026. Full SEC filing compliance. Board audit committee independent. Passes governance basics.

article

SWOT analysis

Strengths

+$240M/yr GSK royalty cash flow at ~95% margin — near-riskless funding source
+Net cash position ($191M) provides refinancing flexibility on 2028 converts
+IST revenue +37% YoY, gross margin expanding as commercial infrastructure scales
+Trades at 10.5x fwd P/E vs pharma sector 19x — meaningful discount to peer median
+$125M buyback authorization signals board confidence in valuation gap

Weaknesses

−Royalty base is declining -4-6%/yr; economic obsolescence over 5-8 years is inevitable
−Armata concentration ($603M of $773M investments) creates single-name mark-to-market risk
−Anti-infective category has structurally weak reimbursement economics (industry track record)
−Sarissa/Denner governance concentration reduces institutional-holder appetite

Opportunities

→Dr. Reddy's distribution deal (Jun 2026) opens ex-US markets for XACDURO with limited capex
→Nortiva Bio spinout could create separate value crystallization event for LYNX platform
→IST FY27 scale to $250M+ enables re-rating to 14-16x fwd P/E multiple
→Armata Phase 3 readout or partnership could revalue strategic investments +50%

Threats

!Advair generic pressure accelerates BREO royalty decay to -10%/yr scenario
!Armata clinical setback triggers writedown and equity retracement
!2028 convertible refinancing at higher rates if stock underperforms
!M&A allocation to underperforming IST tuck-ins destroys optionality vs buyback

article

Summary by assessment area

🟢 Financial risk — Low

$603M cash covers $412M liabilities 1.5x
Positive operating FCF ($100-130M/yr ex-MTM)
Buyback discipline signals capital-return orientation
Convert refi in 2028 manageable given cash balance

🟡 Business risk — Moderate

Royalty decline is real and unstoppable in long term
IST scaling well but anti-infective category is tough
Armata concentration is idiosyncratic single-name risk
Diversification across 3 pools reduces individual failure impact

🔵 Valuation opportunity — Attractive

10.5x fwd P/E vs sector 19x = -45% discount
SotP FV $32.50 vs price $20.97 = +55% base upside
Analyst consensus $35.50 supports thesis
Bear case downside to $14-20 = -33% risk (asymmetric skew positive)

2026-08-10 earnings

Q2 2026 earnings release & guidance update

short-term Impact: High Direction: Binary

First read after Q1 beat. Consensus expects IST +30% YoY and stable royalty trajectory. Beat could re-price 10x fwd P/E; miss shifts focus to royalty attrition curve.

2026-08-10 capital_markets

$125M buyback execution pace disclosure

short-term Impact: Medium Direction: Bullish

Q2 10-Q will disclose shares repurchased under Nov 2025 authorization. Active execution at <$22 supports floor thesis; slow pace signals capital diverted to strategic investments.

2026-09-30 partnership

Dr. Reddy's ex-US XACDURO commercial launch

medium-term Impact: Medium Direction: Bullish

June 2026 distribution & licensing deal begins commercial execution phase. First royalty/milestone economics expected H2 2026. Validates IST international scalability with minimal capex.

2026-11-05 earnings

Q3 2026 earnings — full-year re-guidance likely

medium-term Impact: High Direction: Binary

Historical pattern shows FY guidance refresh at Q3. Positive guide would confirm IST scale-up trajectory; softening implies commercial headwinds.

2026-12-31 regulatory

Armata AP-PA02 Phase 3 clinical progress readout

medium-term Impact: High Direction: Binary

Armata phage therapy Phase 3 read-outs are largest single lever on INVA's $603M strategic investment position. Positive readout revalues NAV; setback triggers -$200-300M markdown.

2027-03-31 strategic

Nortiva Bio (LYNX platform) financing / partnership

long-term Impact: Medium Direction: Bullish

Spinout launched June 2026 with LYNX long-acting oral platform. Series financing round or big-pharma partnership would validate INVA's early-stage stake at a higher mark.

2027-02-25 earnings

FY2026 full year results & FY2027 initial guidance

long-term Impact: High Direction: Binary

Full-year print sets FY27 setup: IST expected to cross $250M, royalty likely to drop below $230M. FY27 EPS guide is key input for re-rating discussion at investor day.

2027-09-30 capital_markets

$261M 2028 convertible notes refinancing decision

long-term Impact: Medium Direction: Neutral

Board must decide by mid-2027 whether to refinance, cash-settle, or convert 2028 notes. Cash balance covers 2.3x; rate environment and stock price at time will drive outcome.

Sources & Disclaimer

Sources: Innoviva investor relations (Q1 2026 press release, 10-Q filings), StockAnalysis.com (real-time price/valuation), Seeking Alpha (Top 10 small-cap value), Simply Wall St, Fintel (short interest), SEC EDGAR (Form 4 insider filings, 8-K materials), BTIG / Cantor Fitzgerald / HC Wainwright (analyst price targets). Market data — last verified close 2026-07-31: INVA $20.97, market cap ~$1.55B, 52W range $16.52-25.15, 73.81M shares outstanding. Short interest: 9.0% of float (6.6M shares). No securities class action, SEC investigation, or short-seller report identified. Prezzo usato: $20.97 (close 2026-07-31, T-1) — sources: StockAnalysis.com, Stock Traders Daily. ⚠️ This document is for informational purposes only and does not constitute financial or investment advice.